Vedolizumab is a Monoclonal Antibody owned by Takeda Pharmaceutical, and is involved in 85 clinical trials, of which 45 were completed, 35 are ongoing, and 5 are planned.

Vedolizumab selectively binds and inhibits alpha4beta7 integrin, which inhibits the binding between alpha4beta7 integrin and MadCAM-1(mucosal adhesion molecule 1) existing mainly in the intestinal mucosa. Integrins are a type of cell surface protein, its main roles are cellular binding to the extracellular matrix and signal transduction from the extracellular matrix. Expression of beta7 has mainly been studied on lymphocytes whereas macrophages have been reported not to express the beta7 integrins. Integrins are trans-membrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM).

The revenue for Vedolizumab is expected to reach a total of $156.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Vedolizumab NPV Report.

Vedolizumab was originated by LeukoSite and is currently owned by Takeda Pharmaceutical.

Vedolizumab Overview

Vedolizumab (Entyvio / Kynteles / Entyvio SC) is a humanized monoclonal antibody produced in Chinese hamster ovary cells. It is formulated as lyophilized powder for solution for intravenous route (infusion) and solution for subcutaneous route of administration. Entyvio is indicated for in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids, in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. Entyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.


The drug candidate is under development for ulcerative colitis, Crohn's disease, pouchitis and graft versus host disease (GvHD) prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. It was also under development for primary sclerosing cholangitis, human immunodeficiency virus (HIV) infection, celiac enteritis, advanced melanoma, and refractory graft versus host disease (GvHD).

Takeda Pharmaceutical Overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY3,569,006 million for the fiscal year ended March 2022 (FY2022), an increase of 11.6% over FY2021. In FY2022, the company’s operating margin was 12.5%, compared to an operating margin of 18.8% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 11.8% in FY2021. The company reported revenues of JPY1,002,307 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – Vedolizumab

Report Segments
  • Innovator (NME)
Drug Name
  • Vedolizumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Immunology
  • Infectious Disease
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.